key: cord-0764476-4cxnbkkm
authors: Bhatt, Arun
title: Clinical trials and Consolidated Standards of Reporting Trials: Continuing concerns of compliance in COVID-19 era
date: 2022-01-06
journal: Perspect Clin Res
DOI: 10.4103/picr.picr_259_21
sha: 6d0f994f6d1de1af380dfedf91e60465441867a0
doc_id: 764476
cord_uid: 4cxnbkkm

nan

The quality of clinical trials could be assessed by reviewing the publications and preprints against Consolidated Standards of Reporting Trials (CONSORT). [3] The CONSORT statement consists of a flow diagram and a checklist of 37 items (25 items + 12 subitems) that guide the reporting of essential items of an RCT. The checklist consists of six sections: (1) title and abstract (one item), (2) introduction (one item), (3) methods (ten items), (4) results (seven items), (5) discussion (three items), and (6) other information (three items). Endorsement of CONSORT by over 600 biomedical journals and prominent editorial organizations such as International Committee of Medical Journal Editors and the World Association of Medical Editors [2, 3] has contributed to improvement in overall reporting quality of RCTs. However, recent studies of quality of published RCTs of COVID-19 interventions appear to reverse this trend.

Yin et al., in a study of evaluation of reporting quality of 53 RCTs in COVID-19 patients, found that the average reporting rate for 37 items in the CONSORT checklist was 53.85%. For the methodological section, the reporting rate was 31.35%. [2] For some critical items -trial design, sample size, allocation concealment, randomization implementation, blinding, ancillary analyses, and protocol -the reporting rate was very low <20%. Only a small number -7 studies (13.21%) reported method of masking concealment, while 9 studies (16.98%) reported the details of blinding. [2] The authors also assessed adherence to CONSORT scoring for each item and subitem and reported a mean overall adherence score of 13.02 ± 3.546 (range 7-22). Gaps in reporting quality of clinical trials are not unique to COVID-19 trials.

In this issue of Journal, Gupta et al. have reported an appraisal of RCTs published in Indian Journal of Pharmacology (IJP). [4] The authors screened 1102 articles published in IJP between 2011 and 2016 and selected 28 RCTs with full-text articles for analysis. They evaluated the quality of these articles against a checklist based on the CONSORT 2010 guidelines for reporting parallel group randomized trials. Deficiencies in the reporting of methods were (1) no description of sample size determination in 7 (25%); (2) mechanism to implement the random allocation sequence not reported in 8 (64.29%) articles; and (3) details of blinding process not available in 12 (42.86%). In the "Results" section, the deficiencies were (1) not reporting precision of effect size in 22 (78.57 %); (2) no participant flow diagram and "intention-to-treat" analysis in 18 (64.29%) articles; and (3) no data on baseline demographics in 8 (28.57%). Trial limitations were not discussed in 9 (32.14%) articles. Another significant omission was no registration of RCT in 19 (67.86%) articles.

Suboptimal adherence to reporting guidelines remains a concern among the clinical research community. In a 2018 systematic review, Jin et al. analyzed whether reporting of medical research adheres to well-known reporting guidelines. [5] They included reviews published over 20 years -between January 1996 and September 2016 -which assessed compliance to reporting standards for clinical trials, systematic reviews, observational studies, meta-analysis, diagnostic accuracy, economic evaluations, and preclinical animal studies. [5] Of the 124 studies assessed, overall adherence to any reporting standards was suboptimal in 87.9%. Compliance to the CONSORT statement was suboptimal in 71 (88%) of 81 RCTS examined. [5] Several factors related to (1) ethical aspects, (2) authorship, (3) study, and (4) journal were associated with improved adherence to reporting guidelines. [5] Ethical factors were: Articles describing details of ethics committee approval, informed consent of participant, and source of funding. [5] Authorship factors were: The level of expertise of author team in research methods and having multiple authors. [5] Low reporting rates for critical items of methodology, results, and discussion may reflect the lack of relevant knowledge of the authors in clinical research methodology and reporting guidelines such as CONSORT. For original research articles, "Methods" section is the most frequently responsible for rejection of the manuscript. [6] Young clinical researchers should be aware of relevant reporting guidelines -CONSORT while preparing the manuscript.

Study design factors were: Well-designed, adequately powered trials providing detailed study methods. [5] Poor reporting of methodological items, e.g., randomization sequence generation, sample size, allocation concealment, and blinding, could result from a perception that the clinical aspects of RCTs are of greater importance and interest compared to study design issues. [7] Some studies have demonstrated a strong association between poorly reported trials and poorly designed or conducted trials. [7] Journal factors were: Journals with high impact or endorsing reporting guidelines. [5] Such journals usually request authors to submit a completed CONSORT checklist, which would be instrumental in enhancing the quality of reporting.

Suboptimal quality of reporting of RCT in publications can result in inaccurate conclusions regarding treatment effect. Reporting guidelines such as CONSORT are an essential tool in the endeavor to ensure consistency in reporting of RCTs. The authors, peer reviewers, and editors should make concerted efforts to meet CONSORT standards.

Methodological quality of COVID-19 clinical research

Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement

CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials

The critical appraisal of randomized controlled trials published in an Indian journal to assess the quality of reporting: A retrospective, cross-sectional study

Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? -A systematic review of reviews: An update

Advice to authors for avoiding flaws in preparation of original research manuscripts

Quality of reporting of modern randomized controlled trials in medical oncology: A systematic review